Cytosurge

Cytosurge

Biotechnologieforschung

Glattbrugg (Zurich), ZH 3.928 Follower:innen

FluidFM® for single-cell manipulation and CRISPR, turning genetic designs into cures, bridging design with manufacturing

Info

Cytosurge develops innovative research solutions using its proprietary FluidFM® technology for precise single-cell manipulation thereby fostering advancements in understanding cellular processes such as the ones that drive cancer. With the FluidFM OMNIUM platform, single-cell extracts, or “biopsies” can be taken from living cells, enabling live-sequencing and temporal transcriptomics analysis. Additionally, the CellEDIT Service provides high-quality genetically engineered cell lines through intra-nuclear injections of CRISPR RNPs. Cytosurge's vision is to unlock novel cures by translating next-generation genetic designs into living cells, thereby enabling longer and healthier lives through precision gene engineering. The Company aims to implement advanced genetically engineered cell lines that bring next-generation therapies to fruition, bridging the gap between genetic design tools and manufacturing, and empowering genetic engineers to realize their visionary concepts. #FluidFM #AFM #mRNA #scRNAseq #LiveSeq #Transcriptomics #Genomics #CellEDIT #CRISPR #GeneEditing #GeneEngineering #CRISPRGeneEditing #GeneticEngineering #CellLineDevelopment #DNAmodifications

Branche
Biotechnologieforschung
Größe
11–50 Beschäftigte
Hauptsitz
Glattbrugg (Zurich), ZH
Art
Privatunternehmen
Gegründet
2009
Spezialgebiete
Single cell manipulation, Single cell injection, Single cell isolation, Single cell extraction, Single cell omics, CRISPR, Gene editing, Virology, Mechanobiology, AFM ADD-ON, AFM und Single Cell

Produkte

Orte

Beschäftigte von Cytosurge

Updates

Verbundene Seiten

Ähnliche Seiten